Delayed Tolerance Through Mixed Chimerism

Status Recruiting

Clinical Trial Summary

This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system

Clinical Trial Description

Recipients of previous living donor (LD) or deceased donor (DD) kidney transplants that were maintained on conventional immunosuppression (I.S.), will receive a conditioning regimen that includes rituximab on study day -6, fludarabine 15 mg/m2/day on days -5 to -3 (3 doses), Cyclophosphamide (30 mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1. Donor hematopoetic stem cells (HSCs) will be infused on study day 0. Methylprednisolone 250mg/day will be started on day 0 and tapered off by day 20 (Fig. 2). Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 12 months following HSC Transplant. The recipients will undergo renal allograft biopsy at 6 months after HSCT. If the I.S. withdrawal criteria are met, I.S. will be slowly tapered off by 9-12 months ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05900401
Study type	Interventional
Source	Massachusetts General Hospital
Contact	Tatsuo Kawai
Phone	617-726-0289
Email	tkawai@mgh.harvard.edu
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	October 1, 2023
Completion date	December 2030

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04510090` - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus	Phase 1
Completed	`NCT02546037` - Clotting With Different Dialyzer Membranes
Recruiting	`NCT02545920` - To Assess Ear Blood Flow During Dialysis
Completed	`NCT02134314` - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI	Phase 1/Phase 2
Recruiting	`NCT01912001` - Virtual Ward for Home Dialysis	N/A
Completed	`NCT01158742` - Live Kidney Donor Study -Renal Function Study	N/A
Completed	`NCT00986947` - Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates	Phase 2
Withdrawn	`NCT00807274` - Renal Function in Adults With Congenital Heart Disease.	N/A
Completed	`NCT00765661` - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients	Phase 2
Completed	`NCT00369382` - Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients	Phase 4
Completed	`NCT00183248` - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients	Phase 1/Phase 2
Enrolling by invitation	`NCT05324878` - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Completed	`NCT05272800` - BIS-guided Fluid Management in HD Patients	N/A
Completed	`NCT03836508` - Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis	N/A
Completed	`NCT01756508` - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury	Phase 2
Completed	`NCT03723668` - Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
Recruiting	`NCT04277377` - Nanoparticle for DSA Removal
Terminated	`NCT00450333` - Dynepo Infrequent Dosing Study	Phase 3
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Recruiting	`NCT04714853` - Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins